Benzenesulfonamides
Medchemexpress LLC HY-100198 1mg Medchemexpress, PI4KIIIbeta-IN-10 CAS:1881233-39-1 Purity:>98%
Medchemexpress, HY-100198 1mg PI4KIIIbeta-IN-10 CAS:1881233-39-1 PI4KIIIbeta-IN-10 is a potent PI4KIIIβ inhibitor with an IC 50 of 3.6 nM. Purity:>98% Medchemexpress has over 10000 novel life-science reagents, reference compounds, APIs and natural compounds for laboratory and scientific use. Other quantity can also be offered.
Medchemexpress LLC YAP/TAZ inhibitor-2 | 2762617-31-0 | 99.8% | 390.33 | 100 MG
YAP/TAZ inhibitor-2 is a potent and orally active TEAD-YAP/TAZ inhibitor with an EC50 value of 3 nM. It demonstrates significant anti-proliferative and anti-tumor activity, making it a valuable compound for research in cancer biology and related fields. This inhibitor is designed to target key pathways involved in cell growth and proliferation.
- Potent and orally active TEAD-YAP/TAZ inhibitor.
- Exhibits anti-proliferative activity.
- Demonstrates anti-tumor effects.
- Valuable for cancer research.
eMolecules 957060-91-2 | 4-(N-(4-Methoxybenzyl)sulfamoyl)phenylboronic acid | Combi-Blocks | MFCD09027228 | 321.150 | C14H16BNO5S | 98.000 | COc1ccc(CNS(=O)(=O)c2ccc(cc2)B(O)O)cc1 | 1g | 117522926
4-(N-(4-Methoxybenzyl)sulfamoyl)phenylboronic acid | Combi-Blocks | 957060-91-2 | MFCD09027228 | 321.150 | C14H16BNO5S | 98.000 | COc1ccc(CNS(=O)(=O)c2ccc(cc2)B(O)O)cc1 | 1g | 117522926
Medchemexpress LLC FASN-IN-3 | 2097262-60-5 | 384.47 | 100 MG
FASN-IN-3 is a fatty acid synthase (FASN) inhibitor, extracted from patent US20170119786A1, compound 242A. It is intended for research use only.
- Reduces IL-1 beta secretion from human PBMC stimulated with LPS or LTA.
- Reduces IL-1 beta from LTA-stimulated monocytes.
- Shows slight reduction of IL-1 beta after LPS stimulation.
- Targets fatty acid synthase (FASN).
Medchemexpress LLC HY-13911 5mg Medchemexpress, Hydroxyfasudil CAS:105628-72-6 Purity:>98%
Medchemexpress, HY-13911 5mg Hydroxyfasudil CAS:105628-72-6 Hydroxyfasudil is a ROCK inhibitor, with IC 50 s of 0.73 and 0.72 μM for ROCK1 and ROCK2 , respectively. Purity:>98% Medchemexpress has over 10000 novel life-science reagents, reference compounds, APIs and natural compounds for laboratory and scientific use. Other quantity can also be offered.
![Medchemexpress LLC 1,4-bis[(3,4-dimethoxyphenyl)sulfonyl]-1,4-diazepane | 447410-57-3 | MFCD02585318 | 98.9% | 500.59 | C21H28N2O8S2 | 25 MG](https://assets.fishersci.com/TFS-Assets/CCG/product-images/5000247734.png-250.jpg)
Medchemexpress LLC 1,4-bis[(3,4-dimethoxyphenyl)sulfonyl]-1,4-diazepane | 447410-57-3 | MFCD02585318 | 98.9% | 500.59 | C21H28N2O8S2 | 25 MG
SB756050 is a selective agonist of the TGR5 (GPBAR1) bile-acid receptor used for in vitro and preclinical research. It is supplied as a characterized compound with defined molecular formula C21H28N2O8S2, molecular weight 500.59, and high purity to support reproducible assay results. Intended for research use only; not for human or clinical applications.
- Selective TGR5 (GPBAR1) agonist suitable for receptor pharmacology studies.
- High purity for reproducible biochemical and cellular assays.
- Available in multiple vial sizes and solution formats for flexibility.
- Stable under recommended storage conditions for long-term use.
- Intended for research use only; not for human use.
Medchemexpress LLC Darunavir Ethanolate | 635728-49-3 | 99.9% | 593.73 | 100 MG
Darunavir ethanolate (TMC114 Ethanolate) is a potent HIV protease inhibitor used to treat and prevent HIV/AIDS. Darunavir has a Ki of 1 nM for wild type HIV-1 protease. It is for research use only and not sold to patients. Darunavir is effective against wild-type and PI-resistant HIV, and has an oral bioavailability of 37%. It needs to be combined with ritonavir, which increases the bioavailability to 82%.
- Potent HIV protease inhibitor
- Active against HIV-1 clinical isolates
- Forms hydrogen bonds with conserved main-chain atoms of Asp29 and Asp30 of the protease
- Greater potency than saquinavir, amprenavir, nelfinavir, indinavir, lopinavir, and ritonavir in an in vitro study
- Effective against wild-type and PI-resistant HIV
- Oral bioavailability increased to 82% when combined with ritonavir
AdipoGen Glimepiride (1 g)
Chemical. CAS: 93479-97-1. Formula: C24H34N4O5S. MW: 490.62. Glimepiride is a long-acting sulfonylurea antidiabetic agent inhibiting ATP-sensitive potassium (KATP) channels in pancreatic beta-cells, which leads to the release of insulin. In addition, Glimepiride increases the activity of intracellular insulin receptors. Studies conducted on adipocytes and skeletal muscle suggest that Glimepiride induces the PI3 kinase (PI3K) and Akt pathway, along with insulin receptor substrate-1/2 and endothelial nitric oxide synthase and stimulates glucose transporter 1 and 4 (GLUT1/4) expression. Glimepiride also increases osteoblast proliferation and differentiation, which is thought to be related to its ability to activate the PI3K and Akt pathway and exhibits neuroprotective benefit, decreasing expression and activity of BACE1 and amyloid-beta (Abeta) in neurons in a PPARgamma-dependent manner.
Medchemexpress LLC AZD2098 | 566203-88-1 | 334.18 | 50 MG
AZD2098 is a potent and selective CC-chemokine receptor 4 (CCR4) inhibitor used for asthma research. It demonstrates pIC50s of 7.8, 8.0, 8.0, and 7.6 for human, rat, mouse, and dog respectively, showing efficacy against antigen-induced inflammatory responses.
- Potent and selective CC-chemokine receptor 4 (CCR4) inhibitor
- Suitable for asthma research
- High purity of 99.91%
- Soluble in DMSO and ethanol for in vitro studies
- Comprehensive documentation available, including Data Sheet, SDS, and COA
Medchemexpress LLC Seclidemstat mesylate | 2044953-70-8 | 99.8% | 547.04 g·mol⁻¹ | C21H27ClN4O7S2 | 10 MG
Seclidemstat mesylate is a research-grade, reversible, noncompetitive inhibitor of lysine-specific demethylase 1 (KDM1A/LSD1) used in preclinical studies. It demonstrates potent biochemical activity and is applied in oncology and virology research, including investigations of SWI/SNF-complex-mutated tumors and fusion-positive sarcomas.
- Reversible, noncompetitive KDM1A (LSD1) inhibitor suitable for biochemical and cell-based assays.
- Demonstrated potency with Ki = 31 nM and IC50 = 13 nM.
- High-purity solid form for reliable experimental reproducibility.
- Available in multiple packaging sizes, including small research quantities.
- Stable when stored under recommended conditions for both short- and long-term use.